(3aS,4S,6S,6aR)-6-allyl-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol | 1535192-99-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3aS,4S,6S,6aR)-6-allyl-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
• 英文别名: (3aS,4S,6S,6aR)-2,2-dimethyl-6-prop-2-enyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
• CAS: 1535192-99-4
• 化学式: C₁₁H₁₈O₃
• 分子量: 198.262
• InChiKey: NWKJWMRSDYVCMG-QEYWKRMJSA-N

物化性质

• 沸点：
  286.4±20.0 °C(Predicted)
• 密度：
  1.045±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3aS,4S,6S,6aR)-6-allyl-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol 在 偶氮二甲酸二异丙酯 、 AD-mix β 、 三苯基膦 作用下， 以 四氢呋喃 、 水 、 叔丁醇 为溶剂， 反应 36.0h， 生成 (S)-3-((3aR,4R,6R,6aS)-6-(6-(bis-tert-butoxycarbonyl)amino-9H-purin-9-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)propane-1,2-diol
  参考文献：
  名称：

  The metathesis reaction for side chain construction in carbocyclic sinefungin analogue synthesis

  摘要：

  The naturally occurring nucleoside sinefungin has found considerable use in biological investigations. More extensive sinefungin studies have been limited because few analogues have been reported due to the synthetic challenges associated with such studies. Reported herein are preparative ways to two carbocyclic sinefungin analogues: 6'-deaminocarbocyclic sinefungin and (S)-6'-hydroxy-6'-deamino-carbocyclic sinefimgin. The synthetic routes were made efficient and practical by the application of two metathesis reactions employing second generation Grubbs catalyst. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2013.12.030
• 作为产物：
  描述：

  (3aR,6S,6aR)-2,2-dimethyl-6-prop-2-enyl-3a,5,6,6a-tetrahydrocyclopenta[d][1,3]dioxol-4-one 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以300 mg的产率得到(3aS,4S,6S,6aR)-6-allyl-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-ol
  参考文献：
  名称：

  [EN] PRMT5 INHIBITOR
  [FR] INHIBITEUR DE PRMT5
  [ZH] PRMT5抑制剂

  摘要：

  一种PRMT5激酶抑制剂，含有所述化合物的药物组合物以及利用所述化合物治疗细胞增殖性疾病，例如癌症的方法。

  公开号：

  WO2023001133A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE PRMT5
  申请人：ANGEX PHARMACEUTICAL INC

  公开号：WO2019112719A1

  公开（公告）日：2019-06-13

  The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

  本公开描述了新型PRMT5抑制剂及其制备方法。还描述了包含这些PRMT5抑制剂的药物组合物以及将它们用于治疗癌症、传染性疾病和其他PRMT5相关疾病的方法。
• NOVEL MONOCYCLIC AND BICYCLIC RING SYSTEM SUBSTITUTED CARBANUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS
  申请人：Janssen Pharmaceutica NV

  公开号：US20190263833A1

  公开（公告）日：2019-08-29

  The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
• HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS
  申请人：ANGEX PHARMACEUTICAL, INC.

  公开号：US20200369667A1

  公开（公告）日：2020-11-26

  The present disclosure describes novel PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMTS inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMTS associated disorders are also described.
• Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US20210371433A1

  公开（公告）日：2021-12-02

  The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.